Preparation method for B cell CD 22 extracellular inhibitive peptide fragment B2285 vaccines

Abstract

The invention provides a preparation method for B cell CD 22 extracellular peptide fragment B2285 vaccines. Sequential eight amino acids from the 85th to the 93rd starting at an amino terminal in a mice CD 22 molecule amino acid sequence, specifically in a sequence of Lys- Thr- Glu- Lys- Asp-Pro- Glu- Ser- Glu, are selected. The sequence is similar to the sequence of Lys- Asp- Gly- Lys- Val- Pro-Ser- Glu, having the sequential eight amino acids from the 81st to the 88th starting at the amino terminal in a human CD 22 molecular amino acid sequence, is located at the same functional region in a spatial structure, and has high homology. A prepared vaccine or a drug composite containing B2285 has the functions of inhibiting B cell proliferation, activating and generating antibody per se, canbe applicable to treating immunologic diseases involved or mediated B cells such as dilated cardiomyopathy testing positive in an anti-myocardial antibody, systemic lupus erythematosus with a positive antibody per se, and the like.

Description

technical field [0001] The invention belongs to the field of biotechnological medicine and biotherapeutics, and relates to a mouse B cell surface characteristic molecule CD22 (mCD22) extracellular peptide B2285 which has the effect of inhibiting B cells. The vaccine or pharmaceutical composition prepared by using B2285 can be used for Treatment of immune diseases in which B cells are involved or mainly mediated, especially immune cardiomyopathy with positive anti-myocardial antibodies and systemic lupus erythematosus with positive autoantibodies. Background technique [0002] Autoimmune diseases are caused by autoimmune disorders. The current treatment is mainly symptomatic and the application of immunosuppressants to relieve symptoms, and there is no specific and safe treatment method. Abnormal activation of B lymphocytes and the generation of pathogenic autoantibodies are one of the important characteristics of autoimmune diseases. Targeting B cells to treat diseases mainl...

AI Technical Summary

Problems solved by technology

[0005] In the existing research on the treatment of SLE, although the anti-CD22 monoclonal antibody Epratuzunab has shown the effect of inhibiting B cell function, due to its short action time, frequent administration, high cost, and the need to introduce exogenous proteins in the production process, it is difficult for The body still has certain immunotoxicity, so it is difficult to promote it in clinical treatment

Images